Danaher CorporationDHR
▼ NegativeCapitalrelevance
Stock fell 9.8% despite beating Q2 revenue and EPS estimates, suggesting market disappointment with the results or guidance.
Impact on stocks 1
Biotech & Genomic Medicine
Danaher CorporationDanaher reported second-quarter 2026 revenue of $6.27 billion, exceeding analyst expectations of $6.1 billion and marking a 5.5% year-on-year increase. Adjusted earnings per share came in at $1.94, a 4.9% beat over the consensus estimate of $1.85. Management slightly raised its full-year adjusted EPS guidance to $8.52 at the midpoint. Despite the beats, the stock fell 9.8% to $181.82 immediately after the results, suggesting the market was hoping for more.
Danaher CorporationStock fell 9.8% despite beating Q2 revenue and EPS estimates, suggesting market disappointment with the results or guidance.